Magnesium acetate

Identification

Name
Magnesium acetate
Accession Number
DB13996  (DBSALT001426)
Type
Small Molecule
Groups
Approved
Description
Not Available
Structure
Thumb
Synonyms
  • acetato de magnesio
  • acetic acid magnesium salt
  • Acetic acid, magnesium salt (2:1)
  • Magnesium di(acetate)
  • magnesium diacetate
  • Mg(II) acetate
Active Moieties
NameKindUNIICASInChI Key
Magnesium cationionicT6V3LHY83822537-22-0JLVVSXFLKOJNIY-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AminosynMagnesium acetate (21 mg/100mL) + Glycine (448 mg/100mL) + Histidine (105 mg/100mL) + L-Alanine (448 mg/100mL) + L-Arginine (343 mg/100mL) + L-Isoleucine (252 mg/100mL) + L-Leucine (329 mg/100mL) + L-Lysine acetate (252 mg/100mL) + L-Phenylalanine (154 mg/100mL) + L-Proline (300 mg/100mL) + L-Threonine (182 mg/100mL) + L-Tryptophan (56 mg/100mL) + L-Tyrosine (31 mg/100mL) + L-Valine (280 mg/100mL) + Methionine (140 mg/100mL) + Phosphoric acid (40 mg/100mL) + Potassium acetate (128 mg/100mL) + Serine (147 mg/100mL) + Sodium Chloride (234 mg/100mL)Injection, solutionIntravenousHospira, Inc.2011-03-23Not applicableUs
Aminosyn 3.5% MMagnesium acetate (21 mg) + Glycine (448 mg) + Histidine (105 mg) + L-Alanine (448 mg) + L-Arginine (343 mg) + L-Isoleucine (252 mg) + L-Leucine (329 mg) + L-Lysine acetate (252 mg) + L-Phenylalanine (154 mg) + L-Proline (300 mg) + L-Threonine (182 mg) + L-Tryptophan (56 mg) + L-Tyrosine (31 mg) + L-Valine (280 mg) + Methionine (140 mg) + Potassium acetate (128 mg) + Serine (147 mg) + Sodium Chloride (234 mg)LiquidIntravenousAbbott1980-12-311999-08-09Canada
FreAmine IIIMagnesium acetate (0.054 g/100mL) + Glycine (0.42 g/100mL) + Histidine (0.085 g/100mL) + L-Alanine (0.21 g/100mL) + L-Arginine (0.29 g/100mL) + L-Cysteine hydrochloride (0.014 g/100mL) + L-Isoleucine (0.21 g/100mL) + L-Leucine (0.27 g/100mL) + L-Lysine acetate (0.22 g/100mL) + L-Phenylalanine (0.17 g/100mL) + L-Proline (0.34 g/100mL) + L-Threonine (0.12 g/100mL) + L-Tryptophan (0.046 g/100mL) + L-Valine (0.2 g/100mL) + Methionine (0.16 g/100mL) + Phosphoric acid (0.040 g/100mL) + Potassium Chloride (0.15 g/100mL) + Serine (0.18 g/100mL) + Sodium Chloride (0.12 g/100mL) + Sodium acetate trihydrate (0.2 g/100mL)Injection, solutionIntravenousB. Braun Medical Inc.1971-09-242013-08-01Us
Hyperlyte (multi-electrolyte Concentrate)Magnesium acetate (860 mg) + Calcium acetate (440 mg) + Sodium gluconate (1.09 g) + Potassium Chloride (2.46 g) + Potassium acetate (690 mg) + Sodium acetate (2.72 g)LiquidIntravenousB. Braun Medical Inc.1998-09-04Not applicableCanada
LypholyteMagnesium acetate (860 mg) + Calcium acetate (440 mg) + Sodium gluconate (1.1 g) + Potassium Chloride (2.5 g) + Potassium acetate (690 mg) + Sodium acetate (2.7 g)SolutionIntravenousPartners Health Care, Inc.1996-08-142008-01-10Canada
Lypholyte Multi-electrolyte Conc InjMagnesium acetate (43 mg) + Calcium acetate (22 mg) + Sodium gluconate (55 mg) + Potassium Chloride (125 mg) + Potassium acetate (34.5 mg) + Sodium acetate (135 mg)LiquidIntravenousLyphomed, Division Of Fujisawa Canada Inc.1991-12-311996-09-10Canada
Normosol-M & 5% DextroseMagnesium acetate (0.021 g) + Dextrose, unspecified form (5 g) + Potassium acetate (0.128 g) + Sodium Chloride (0.234 g)SolutionIntravenousIcu Medical Canada Inc1965-12-31Not applicableCanada
Normosol-M and DextroseMagnesium acetate (21 mg/100mL) + D-glucose monohydrate (5 g/100mL) + Potassium acetate (128 mg/100mL) + Sodium Chloride (234 mg/100mL)Injection, solutionIntravenousHospira, Inc.1975-08-131975-08-14Us
Plasma-lyte 56 5% Dextrose InjMagnesium acetate (32 mg) + Dextrose, unspecified form (5 g) + Potassium acetate (128 mg) + Sodium Chloride (234 mg)LiquidIntravenousBaxter Laboratories1990-12-312014-04-17Canada
ProcalAmineMagnesium acetate (0.054 g/100mL) + Calcium acetate (0.026 g/100mL) + Glycerin (3 g/100mL) + Glycine (0.42 g/100mL) + Histidine (0.085 g/100mL) + L-Alanine (0.21 g/100mL) + L-Arginine (0.29 g/100mL) + L-Cysteine hydrochloride (0.014 g/100mL) + L-Isoleucine (0.21 g/100mL) + L-Leucine (0.27 g/100mL) + L-Lysine acetate (0.22 g/100mL) + L-Phenylalanine (0.17 g/100mL) + L-Proline (0.34 g/100mL) + L-Threonine (0.12 g/100mL) + L-Tryptophan (0.046 g/100mL) + L-Valine (0.2 g/100mL) + Methionine (0.16 g/100mL) + Phosphoric acid (0.041 g/100mL) + Potassium Chloride (0.15 g/100mL) + Serine (0.18 g/100mL) + Sodium Chloride (0.12 g/100mL) + Sodium acetate trihydrate (0.2 g/100mL)InjectionIntravenousB. Braun Medical Inc.1982-05-06Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
NutrilyteMagnesium acetate (43 mg/1mL) + Calcium acetate (22 mg/1mL) + Sodium gluconate (55 mg/1mL) + Potassium Chloride (125 mg/1mL) + Potassium acetate (34.5 mg/1mL) + Sodium acetate trihydrate (135 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-09-302013-05-08Us
Categories
UNII
0E95JZY48K
CAS number
142-72-3
Weight
Average: 142.393
Monoisotopic: 142.01165037
Chemical Formula
C4H6MgO4
InChI Key
UEGPKNKPLBYCNK-UHFFFAOYSA-L
InChI
InChI=1S/2C2H4O2.Mg/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2
IUPAC Name
magnesium(2+) diacetate
SMILES
[Mg++].CC([O-])=O.CC([O-])=O

Pharmacology

Indication
Not Available
Associated Therapies
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
USodium/potassium-transporting ATPase subunit alpha-1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Magnesium acetate.
AgmatineThe therapeutic efficacy of Magnesium acetate can be decreased when used in combination with Agmatine.
AlcuroniumThe therapeutic efficacy of Alcuronium can be increased when used in combination with Magnesium acetate.
AlfentanilThe therapeutic efficacy of Magnesium acetate can be decreased when used in combination with Alfentanil.
AlphacetylmethadolThe therapeutic efficacy of Magnesium acetate can be decreased when used in combination with Alphacetylmethadol.
AlphaprodineThe therapeutic efficacy of Magnesium acetate can be decreased when used in combination with Alphaprodine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Magnesium acetate.
AmiodaroneThe therapeutic efficacy of Magnesium acetate can be decreased when used in combination with Amiodarone.
AmlodipineThe therapeutic efficacy of Magnesium acetate can be decreased when used in combination with Amlodipine.
ApramycinThe risk or severity of neuromuscular blockade can be increased when Apramycin is combined with Magnesium acetate.
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
8556
ChEBI
62964
ChEMBL
CHEMBL1200691
Wikipedia
Magnesium_acetate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntravenous
SolutionIntravenous
LiquidIntravenous
Injection, solution, concentrateIntravenous
InjectionIntravenous
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility98.2 mg/mLALOGPS
logP0.29ALOGPS
logP-0.22ChemAxon
logS-0.16ALOGPS
pKa (Strongest Acidic)4.54ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity23.48 m3·mol-1ChemAxon
Polarizability4.96 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as acetate salts. These are organic compounds containing acetic acid as its acid component.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Carboxylic acid derivatives
Direct Parent
Acetate salts
Alternative Parents
Monocarboxylic acids and derivatives / Carboxylic acids / Organic salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Acetate salt / Monocarboxylic acid or derivatives / Carboxylic acid / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic salt / Organooxygen compound / Carbonyl group / Aliphatic acyclic compound
Molecular Framework
Not Available
External Descriptors
magnesium salt (CHEBI:62964)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Buchachenko AL, Kuznetsov DA, Berdinskii VL: [New mechanisms of biological effects of electromagnetic fields]. Biofizika. 2006 May-Jun;51(3):545-52. [PubMed:16808357]
  2. Sirijovski N, Olsson U, Lundqvist J, Al-Karadaghi S, Willows RD, Hansson M: ATPase activity associated with the magnesium chelatase H-subunit of the chlorophyll biosynthetic pathway is an artefact. Biochem J. 2006 Dec 15;400(3):477-84. [PubMed:16928192]
  3. Balasubramaniyan V, Nalini N: Leptin alters brain adenosine triphosphatase activity in ethanol-mediated neurotoxicity in mice. Singapore Med J. 2006 Oct;47(10):864-8. [PubMed:16990961]
  4. Nogovitsina OR, Levitina EV: Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Behav Physiol. 2007 Mar;37(3):199-202. [PubMed:17294093]

Drug created on February 23, 2018 14:26 / Updated on November 03, 2018 15:40